Recursion Pharmaceuticals, Inc.
RXRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001601830
In the last 90 days, Recursion Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 344 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in Recursion Pharmaceuticals, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 192
- +36 vs. Q2 2023
- Shares held
- 152.3M
- +24.7M (+19.4%) vs. Q2 2023
- Total value
- $1.16B
- +$212.0M (+22.3%) vs. Q2 2023
- New holders
- 56
- 74 more added
- Sold out
- 20
- 38 more reduced
2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RXRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 344 | $1.33B |
| Q1 2026 | 335 | $1.03B |
| Q4 2025 | 335 | $1.33B |
| Q3 2025 | 322 | $1.58B |
| Q2 2025 | 333 | $1.57B |
| Q1 2025 | 337 | $1.63B |
| Q4 2024 | 316 | $2.06B |
| Q3 2024 | 268 | $1.74B |
| Q2 2024 | 270 | $1.89B |
| Q1 2024 | 248 | $2.12B |
| Q4 2023 | 199 | $2.04B |
| Q3 2023 | 192 | $1.16B |
| Q2 2023 | 158 | $952.8M |
| Q1 2023 | 159 | $841.4M |
| Q4 2022 | 144 | $954.0M |
| Q3 2022 | 146 | $1.21B |
| Q2 2022 | 133 | $861.1M |
| Q1 2022 | 128 | $680.3M |
| Q4 2021 | 126 | $1.62B |
| Q3 2021 | 84 | $1.26B |
| Q2 2021 | 75 | $1.71B |
| Q1 2021 | 1 | $1.00K |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Recursion Pharmaceuticals, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Manchester Capital Management LLC | 0 | $0 | 0.00% | −26,880−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −19,495−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −19,801−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −18,917−100.0% | Sold out |
| Vident Investment Advisory, LLC | 0 | $0 | 0.00% | −17,849−100.0% | Sold out |
| Centaurus Financial, Inc. | 0 | $0 | 0.00% | −13,242−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −12,314−100.0% | Sold out |
| Accel Wealth Management | 0 | $0 | 0.00% | −10,330−100.0% | Sold out |
| Delphia (USA) Inc. | 0 | $0 | 0.00% | −10,212−100.0% | Sold out |
| O'Dell Group, LLC | 0 | $0 | 0.00% | −1,175−100.0% | Sold out |
| Cape Investment Advisory, Inc. | 0 | $0 | 0.00% | −250−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −115−100.0% | Sold out |
| Pictet Asset Management SA | – | – | – | – | Not filed |
| BDO Wealth Advisors, LLC | – | – | – | – | Not filed |